ANI Pharmaceuticals, Inc. (ANIP) Shares Bought by Nomura Holdings Inc.

Nomura Holdings Inc. grew its holdings in shares of ANI Pharmaceuticals, Inc. (NASDAQ:ANIP) by 0.2% during the second quarter, according to its most recent 13F filing with the SEC. The institutional investor owned 209,349 shares of the specialty pharmaceutical company’s stock after buying an additional 448 shares during the period. Nomura Holdings Inc. owned approximately 1.80% of ANI Pharmaceuticals worth $9,744,000 as of its most recent filing with the SEC.

Several other institutional investors have also bought and sold shares of the business. Vanguard Group Inc. boosted its holdings in shares of ANI Pharmaceuticals by 8.1% during the 2nd quarter. Vanguard Group Inc. now owns 476,948 shares of the specialty pharmaceutical company’s stock worth $22,322,000 after buying an additional 35,722 shares in the last quarter. First Manhattan Co. boosted its holdings in shares of ANI Pharmaceuticals by 35.3% during the 2nd quarter. First Manhattan Co. now owns 376,395 shares of the specialty pharmaceutical company’s stock worth $17,615,000 after buying an additional 98,300 shares in the last quarter. Dimensional Fund Advisors LP boosted its holdings in shares of ANI Pharmaceuticals by 91.1% during the 2nd quarter. Dimensional Fund Advisors LP now owns 339,268 shares of the specialty pharmaceutical company’s stock worth $15,878,000 after buying an additional 161,743 shares in the last quarter. Renaissance Technologies LLC boosted its holdings in shares of ANI Pharmaceuticals by 7.0% during the 2nd quarter. Renaissance Technologies LLC now owns 297,400 shares of the specialty pharmaceutical company’s stock worth $13,918,000 after buying an additional 19,400 shares in the last quarter. Finally, Bank of America Corp DE boosted its holdings in shares of ANI Pharmaceuticals by 25.5% during the 1st quarter. Bank of America Corp DE now owns 197,224 shares of the specialty pharmaceutical company’s stock worth $9,764,000 after buying an additional 40,111 shares in the last quarter. Hedge funds and other institutional investors own 55.86% of the company’s stock.

A number of equities analysts have issued reports on ANIP shares. Guggenheim restated a “buy” rating and set a $80.00 price target on shares of ANI Pharmaceuticals in a report on Tuesday, July 4th. Canaccord Genuity restated a “buy” rating and set a $60.00 price target on shares of ANI Pharmaceuticals in a report on Wednesday, August 9th. BidaskClub cut ANI Pharmaceuticals from a “hold” rating to a “sell” rating in a report on Saturday, August 5th. Finally, Zacks Investment Research upgraded ANI Pharmaceuticals from a “sell” rating to a “hold” rating in a report on Wednesday, July 5th. Four investment analysts have rated the stock with a hold rating and two have assigned a buy rating to the company’s stock. The company presently has an average rating of “Hold” and a consensus price target of $65.33.

ILLEGAL ACTIVITY WARNING: This article was first posted by Community Financial News and is the sole property of of Community Financial News. If you are reading this article on another domain, it was stolen and reposted in violation of US and international copyright & trademark law. The legal version of this article can be read at https://www.com-unik.info/2017/10/11/ani-pharmaceuticals-inc-anip-shares-bought-by-nomura-holdings-inc.html.

Shares of ANI Pharmaceuticals, Inc. (NASDAQ:ANIP) traded down 0.1545% during trading on Wednesday, hitting $53.8167. The stock had a trading volume of 10,005 shares. The firm has a 50 day moving average price of $50.03 and a 200-day moving average price of $48.29. ANI Pharmaceuticals, Inc. has a 52 week low of $42.23 and a 52 week high of $69.30. The stock has a market capitalization of $626.32 million, a price-to-earnings ratio of 116.9928 and a beta of 3.05.

ANI Pharmaceuticals (NASDAQ:ANIP) last released its quarterly earnings results on Thursday, August 3rd. The specialty pharmaceutical company reported $0.98 earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of $0.79 by $0.19. ANI Pharmaceuticals had a return on equity of 22.70% and a net margin of 3.35%. The company had revenue of $44.80 million for the quarter, compared to analyst estimates of $43.20 million. During the same period in the previous year, the company posted $1.11 earnings per share. The firm’s revenue was up 43.0% on a year-over-year basis. On average, equities research analysts forecast that ANI Pharmaceuticals, Inc. will post $3.84 EPS for the current fiscal year.

ANI Pharmaceuticals Company Profile

ANI Pharmaceuticals, Inc is an integrated specialty pharmaceutical company. The Company is engaged in developing, manufacturing and marketing branded and generic prescription pharmaceuticals. The Company focuses on areas, including controlled substances, anti-cancer (oncolytics), hormones and steroids, and complex formulations.

Institutional Ownership by Quarter for ANI Pharmaceuticals (NASDAQ:ANIP)

What are top analysts saying about ANI Pharmaceuticals Inc.? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for ANI Pharmaceuticals Inc. and related companies.

Comments

Leave a Reply


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on Google Plus
share on reddit